中国医学创新2025，Vol.22Issue(28)：33-37,5.DOI:10.3969/j.issn.1674-4985.2025.28.008
黄葵胶囊联合复方α-酮酸片治疗非透析CKD 4～5期患者的效果
Effect of Huangkui Capsules Combined with Compound α-Ketoacid Tablets in the Treatment of Patients with Non-dialysis CKD at Stage 4-5
摘要
Abstract
Objective:To observe the effect of Huangkui Capsules combined with Compound α-Ketoacid Tablets in the treatment of patients with non-dialysis chronic kidney disease(CKD)at stage 4-5,as well as its influence on renal function,nutritional status and clinical symptoms.Method:A total of 80 patients with non-dialysis CKD at stage 4-5 who were treated at Pingxiang Traditional Chinese Medicine Hospital from April 2023 to December 2024 were selected and divided into control group and experimental group by random number table method,with 40 cases in each group.The control group was treated with conventional methods plus Compound α-Ketoacid Tablets,while the experimental group was orally administered Huangkui Capsules on the basis of the control group.Both groups were treated for a period of 12 weeks.The clinical efficacy of the two groups and the changes in clinical symptoms,renal function and nutritional status before and after treatment were compared,and the incidence of adverse reactions in the two groups was statistically analyzed.Result:The total response rate in the experimental group reached 92.50%,higher than 75.00%in the control group(x2=4.501,P=0.034).After treatment,the scores for main symptoms and secondary symptoms,and total score of clinical symptoms decreased in both groups,above scores of the experimental group were lower compared with the control group(P<0.05).After treatment,the levels of Scr,BUN,β2-microglobulin(β2-MG)and uric acid(UA)decreased in both groups,the levels were lower in the experimental group(P<0.05).After treatment,the levels of total protein(TP),albumin(ALB),Hb and transferrin(TRF)in both groups increased,and the levels were higher in the experimental group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(x2=0.157,P=0.692).Conclusion:The combination of Huangkui Capsules and Compound α-Ketoacid Tablets in the treatment of patients with non-dialysis CKD at stage 4-5 can improve clinical symptoms and renal function indicators,enhance the nutritional status of patients,and has good safety.关键词
黄葵胶囊/复方α-酮酸片/慢性肾脏病/肾功能/营养状态Key words
Huangkui Capsules/Compound α-Ketoacid Tablets/Chronic kidney disease/Renal function/Nutritional status引用本文复制引用
刘刚,段莎,钟招梅,李建军..黄葵胶囊联合复方α-酮酸片治疗非透析CKD 4～5期患者的效果[J].中国医学创新,2025,22(28):33-37,5.基金项目
江西省中医药管理局科技计划项目(2023B0255) （2023B0255）
